CLSA maintains buy on Sun Pharma:


Company’s specialty ramp-up is progressing well. Expect profit contribution from specialty to rise sharply in the next 2-3 years and FY21 annual report reiterates commitment to this segment.

There was a sharp decline in SG&A for global specialty business but some costs may return, CLSA added.

Sun Pharmaceutical Industries was quoting at Rs 787.90, up Rs 3.95, or 0.50 percent on the BSE.

News source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button